Search / Trial NCT06228027

External Validation os the ACME Scoring System

Launched by HOSPITAL DEL MAR · Jan 18, 2024

Trial Information

Current as of October 03, 2024

Not yet recruiting

Keywords

Acute Cholecystitis Cholecystectomy Tokyo Guidelines Postoperative Complications Mortality High Risk Patient

Description

This is a prospective multicenter observational study of 10.000 adults with ACC during 2 consecutive years (2025/2026), including baseline demographic characteristics, comorbidity severity defined as Charlson Comorbidity Index (CCI), ASA Score, Tokyo Guidelines severity classification and the new ACME Scoring system. The primary outcome is to study the prediction of mortality of ACME score. Secondary outcomes include complications following Clavien-Dindo's classification, C-statistic, and ROC Curves.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Acute Calculous Cholecystitis
  • Exclusion Criteria:
  • * Acute Cholangitis
  • * Chronic Cholecystitis
  • * Neoplasia
  • * Acute Pancreatitis
  • * Pregnant

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0